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 Kelompok Statistic Std. Error 
CKMB 
Kontrol 
Mean 217,29 17,548 
95% Confidence Interval for 
Mean 
Lower Bound 174,35  
Upper Bound 260,22  
5% Trimmed Mean 216,04  
Median 215,00  
Variance 2155,571  
Std. Deviation 46,428  
Minimum 152  
Maximum 305  
Range 153  
Interquartile Range 41  
Skewness ,883 ,794 
Kurtosis 2,429 1,587 
Perlakuan 1 
Mean 224,57 35,922 
95% Confidence Interval for 
Mean 
Lower Bound 136,67  
Upper Bound 312,47  
5% Trimmed Mean 223,02  
Median 199,00  
Variance 9032,619  
Std. Deviation 95,040  
Minimum 117  
Maximum 360  
Range 243  
Interquartile Range 192  
Skewness ,245 ,794 
Kurtosis -1,621 1,587 
Perlakuan 2 
Mean 141,14 22,938 
95% Confidence Interval for 
Mean 
Lower Bound 85,01  
Upper Bound 197,27  





Median 118,00  
Variance 3683,143  
Std. Deviation 60,689  
Minimum 93  
Maximum 265  
Range 172  
Interquartile Range 77  
Skewness 1,781 ,794 





Tests of Normality kadar CKMB 
 Kelompok Shapiro-Wilk 
 Statistic df Sig. 
Kadar 
CKMB 
Kontrol ,912 7 ,410 
Perlakuan 1 ,923 7 ,496 
Perlakuan 2 ,782 7 ,027 
*. This is a lower bound of the true significance. 
a. Lilliefors Significance Correction 
Tests of Normality kadar CKMB yang ditransformasi menggunakan fungsi Log 10 
 Kelompok Shapiro-Wilk 




Kontrol ,940 7 ,639 
Perlakuan 1 ,916 7 ,442 
Perlakuan 2 ,866 7 ,171 
*. This is a lower bound of the true significance. 














Kadar CKMB yang ditransformasi 
 Sum of Squares df Mean Square F Sig. 
Between Groups ,188 2 ,094 3,937 ,038 
Within Groups ,430 18 ,024   




















Perlakuan 1 ,013376231 ,082573017 ,873 -,16010324 ,18685570 
Perlakuan 2 ,207021471* ,082573017 ,022 ,03354200 ,38050094 
Perlakuan 1 
Kontrol -,013376231 ,082573017 ,873 -,18685570 ,16010324 
Perlakuan 2 ,193645240* ,082573017 ,031 ,02016577 ,36712471 
Perlakuan 2 
Kontrol -,207021471* ,082573017 ,022 -,38050094 -,03354200 
Perlakuan 1 -,193645240* ,082573017 ,031 -,36712471 -,02016577 





Test of Homogeneity of Variances Kadar CKMB 
yang ditransformasi 
 
Levene Statistic df1 df2 Sig. 
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